Evolution of patient demographics, baseline clinical characteristics and outcomes in Phase 3 trials of biologics (TNFi, IL12/23i, IL17i, IL23i), PDE4i and TYK2i for psoriasis
Abstract Background Psoriasis, a common chronic inflammatory skin disease with major impact on quality of life, is associated with several comorbidities. A better understanding of the pathogenesis of psoriasis has led to the development and approval of new therapeutic strategies such as biologics of...
Автори: | Sara Peeters, Kurt De Vlam, Hugo Boonen, Canan Güvenç, Tom Hillary |
---|---|
Формат: | Стаття |
Мова: | English |
Опубліковано: |
Wiley
2024-06-01
|
Серія: | JEADV Clinical Practice |
Предмети: | |
Онлайн доступ: | https://doi.org/10.1002/jvc2.355 |
Схожі ресурси
Схожі ресурси
-
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses – IL PSO (Italian landscape psoriasis)
за авторством: Luigi Gargiulo, та інші
Опубліковано: (2024-01-01) -
The Roles of IL-17, IL-21, and IL-23 in the <i>Helicobacter pylori</i> Infection and Gastrointestinal Inflammation: A Review
за авторством: Astri Dewayani, та інші
Опубліковано: (2021-04-01) -
IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy
за авторством: James G. Krueger, та інші
Опубліковано: (2024-04-01) -
A non-clinical comparative study of IL-23 antibodies in psoriasis
за авторством: Li Zhou, та інші
Опубліковано: (2021-01-01) -
Association between polymorphisms of <i>IL33</i> and <i>IL37</i> and atopic dermatitis
за авторством: O. A. Svitich, та інші
Опубліковано: (2024-11-01)